iX Biopharma (SGX:42C) 3-Year Revenue Growth Rate

: 58.70% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

iX Biopharma's Revenue per Share for the six months ended in Dec. 2023 was S$0.00.

During the past 12 months, iX Biopharma's average Revenue per Share Growth Rate was 40.00% per year. During the past 3 years, the average Revenue per Share Growth Rate was 58.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 10 years, the highest 3-Year average Revenue per Share Growth Rate of iX Biopharma was 166.80% per year. The lowest was -53.60% per year. And the median was 49.40% per year.

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, iX Biopharma's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

iX Biopharma 3-Year Revenue Growth Rate Distribution

For the Drug Manufacturers industry and Healthcare sector, iX Biopharma's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where iX Biopharma's 3-Year Revenue Growth Rate falls into.

iX Biopharma 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

iX Biopharma (SGX:42C) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

iX Biopharma 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of iX Biopharma's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

iX Biopharma (SGX:42C) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » iX Biopharma Ltd (SGX:42C) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Kim Seng Promenade, No. 14-01, Great World City East Lobby, Singapore, SGP, 237994

Website

https://www.ixbiopharma.com

iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in United States of America, Singapore, Australia, and China, of which the majority of the revenue comes from the United States of America. The company generates the majority of its revenue from the sale of specialty pharmaceutical products.

iX Biopharma (SGX:42C) Headlines

No Headlines